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Improved regional selectivity of hepatic arterial mitomycin 
by starch microspheres 
Biodegradable starch microspheres, 40 /Jill in diameter, were administered through hepatic 
arterial catheters in 16 subjects with primary and metastatic liver tumors. These microspheres 
temporarily obstruct blood flow at the precapillary arteriole (microcirculation) level. Our study' 
was undertaken to determine whether such occlusion would enhance hepatic deposition of, and 
thereby decrease systemic exposure to, simultaneously administered hepatic arterial mitomycin C 
(mito). When mito (10 mg/m2 over 1 min) was given with 90 x 106 microspheres (10 subjects), 
there was a 17% to 70% reduction in systemic mito exposure. When mito (10 mg/m2 over I 
min) was given with 36 x 106 microspheres (six subjects), there was a 15% to 60% reduction in 
systemic exposure, which may correlate with dose-dependent shunting (8% to 29%) through the 
liver to the lung (and hence to the systemic circulation), attributed to the starch tnicrospheres. 
No life-threatening myelosuppression was noted; hepatic toxicity consisted of transient pain and 
elevation of liver enzymes. 
John W. Gyves, M.D., William D. Ensminger, M.D., Ph.D., Donald VanHarken, Ph.D., 
John Niederhuber, M.D., Philip Stetson, M.D., Ph.D., and Suzette Walker, R.N. 
Ann Arbor, Mich., and Syracuse, N. Y. 
Division of Hematology/Oncology, Department of Medicine, and Division of Surgical Oncology, 
Department of Surgery, University of Michigan Medical School, Ann Arbor and Bristol 
Laboratories, Syracuse 
Based on pharmacokinetic principles, it 
should be possible to markedly increase the drug 
exposure of tumor within the hepatic arterial 
watershed by direct hepatic arterial infusion with 
drugs that have a high total body clearance and 
short plasma t1/2 .7 9 Fluorouracil and fluorode- 
oxyuridine (FUDR),'5 thymidine," doxorubicin 
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HC1,'8 carmustine (BCNU),16 dichlorometho- 
trexate,w mitomycin,"° and cisplatin26 have been 
studied. The need for a reliable and convenient 
drug delivery system'2 and a means of deter- 
mining actual flow distribution to the entire 
liver,24' 25' 32 have been recently stressed. The 
increase in local drug concentration with re- 
gional arterial infusions depends largely on 
blood flow rate in the artery infused.' A low 
arterial blood flow rate will ensure a high local 
drug level. The recent availability of degradable 
starch microspheres (DSM) has allowed study 
of transient arteriolar-capillary blockade (as a 
means to decrease blood flow) and the effect of 
such blockade on the kinetics of concurrent he- 
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Capillary bed 
Fig. 1. Schematic representation of starch microsco- 
phere induced precapillary arteriole occlusion and 
drug egress from blocked blood column. Top, Micro- 
spheres (large open spheres) lodged in precapillary 
arteriole with drug (small dots) movement (arrow) 
out of blocked blood column. Middle, Movement of 
microspheres (smaller open spheres) into capillary 
bed as they are digested, with continued restriction 
of blood flow and drug movement. Bottom, Further 
digestion of microspheres (small open spheres) and 
egress of drug into venule. 
patic arterial drug administration.3. 8' 29 In one 
report, 90 x 108 microspheres with BCNU in 
the solution reduced systemic plasma levels of 
BCNU by as much as 90% (range 30% to 
90%).8 This reduction in systemic exposure 
with DSM implies greater deposition of drug in 
the organ infused. 
When a drug is injected into the hepatic ar- 
tery, a fraction of the drug diffuses into the 
surrounding tissue, and another fraction leaks 
into the systemic circulation. Some drugs, such 
as BCNU, will also break down spontaneously 
in plasma. As schematically illustrated in Fig. 
1, when a drug is mixed with starch micro- 
spheres and injected into the hepatic artery, the 
microspheres may cause transient blockage of 
flow through the capillary bed. The drug is then 
trapped in a relatively stationary fluid column, 
allowing more exposure time to the surrounding 
tissues. With time the microspheres dissolve 
and the flow through the capillary bed is re- 
ACUP = Adenocarcinoma of unknown primary. 
stored. For appropriately selected drugs, such 
an approach may have therapeutic importance 
based on differences in tumor and normal tissue 
microcirculation,' but as a result of the ob- 
structed flow, a variable degree of intrahepatic 
shunting may occur." The magnitude of the 
shunt may influence the regional selectivity of 
such an approach. 
The potential for decreased systemic expo- 
sure because of increased local hepatic uptake 
of mito with concurrent hepatic arterial micro- 
spheres was examined. Mito was selected be- 
cause it has activity in a variety of tumors that 
metastasize to the liver, as well as a short 
plasma t1/2 and high total body clearance 
(characteristics that are essential in the rational 
use of a drug for regional chemotherapy)* 9' 13 
Myelosuppression is also dose limiting when 
mito is given systemically. Thus a reduction in 
systemic exposure when mito is used with mi- 
crospheres should lead to less myelosuppression 
with diminished chances for infection and 
bleeding. 
Materials and methods 
The DSM (Pharmacia) consist of specially 
formulated cross-linked starch spheres 40 ± 5 
atm in diameter. The degree of cross-linkage is 
highest in the outer shell, so that the spherical 
shape is maintained until the final stage of disso- 
lution. The microspheres are degraded by serum 
amylase and become progressively smaller in 
size, with a t1/2 for complete dissolution be- 
tween 15 and 30 min in vitro (in normal serum). 
Table I. Patient characteristics 
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Diagnosis 
Colorectal cancer 12 
Cholangiocarcinoma 1 
Pancreatic cancer 1 












Table II. Effect of starch microspheres 
(15 ml) on systemic mitomycin exposure 
(10 subjects; 12 courses) 







The spheres are stable in a dry state and can be 
stored at room temperature. Concentration of 
the standard DSM suspension is 6 million 
microspheres/ml (60 mg/m1). 
Our subjects were 16 patients with incurable 
liver tumors (Table I) in whom systemic chemo- 
therapy and hepatic arterial therapy with FUDR 
had failed. A percutaneous catheter was placed 
in the hepatic artery through the brachial or 
femoral route (five subjects), or a Silastic cathe- 
ter was placed surgically (11 subjects) to per- 
fuse the entire liver as documented by nuclear 
angiography .24' 25' 32 On two separate days, 10 
subjects received mito (10 mg/m2) alone and 
the same dose reconstituted in 15 ml starch mi- 
crospheres (90 x 106 microspheres) injected 
into the hepatic artery catheter over 1 min. This 
dose of microspheres was based on prior an- 
giographic studies that confirmed transient ob- 
struction of hepatic arterial flow after injection 
of 90 x 106 particles. Subsequently, six addi- 
tional subjects were treated with mito (10 mg/ 
m2) with and without 6 ml starch microspheres 
(36 x 106 microspheres) to evaluate the effect of 
shunting through the liver on systemic drug ex- 
posure. Peripheral venous blood samples were 
obtained at 0, 1, 2, 4, 6, 8, 10, 15, 20, 30, 45, 
and 60 min after injection on each occasion, and 
the plasma was assayed for mito by a sensitive 
microbiologic assay or HPLC. The AUC with 
time was used as a measure of systemic expo- 
sure. Complete blood counts and liver enzyme 
determinations were obtained weekly to monitor 
toxicity. 
Before treatment, the flow distribution to the 
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Fig. 2. Effect of starch microspheres on systemic 
mito level with hepatic arterial injection. Mito alone ( ); mito with 90 x 106 DSM (o o). 
entire liver was determined by injecting 4 mCi 
of technetium 99m macroaggregated albumin 
(TcMAA) over 1 min through the hepatic arte- 
rial catheter.24' 25 These TcMAA particles are 
approximately 35 tan in size and are trapped in 
the first precapillary arteriole encountered. Thus 
scans obtained after such injection reflect the 
microcirculation patent at the time of injection. 
A 15-ml suspension of starch microspheres 
was mixed with 5 mCi TcMAA and aliquoted 
into five 3-ml syringes, each containing equal 
amounts of tracer and microspheres. One mil- 
licurie TcMAA was injected into the hepatic 
artery to obtain a baseline nuclear angiogram. 
Thereafter, repeated 3-ml doses of TcMAA- 
spiked starch microspheres were injected 
through the hepatic artery, allowing sufficient 
time (I min) between doses to obtain scintillation 
data over the liver, abdomen, and lungs. Based 
on these data, changes in the amount of isotope 
(counts) delivered to the entire liver and areas 
outside the liver (lung and stomach and/or small 
bowel) can be calculated at each dose and a 
percent shunt index (PSI) determined. The PSI 
was calculated as: 
Total field counts liver counts PSI 100% Total field counts 
0-15 23.40 12.94 P < 0.01 
(11.54-33.70) (5.81-18.35) 
0-30 37.64 21.50 P < 0.01 
(17.99-57.02) (10.46-29.93) 
0-60 58.26 36.29 P < 0.01 
With Without 
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Table III. Ratio of systemic mitomycin 
exposure (AUC) with (15 ml) microspheres 
and without microspheres (10 subjects; 
12 courses) 
Subjects with evidence of flow to the stomach 
and/or small bowel were excluded from treat- 
ment, as were those with a baseline shunt of 
more than 30% of activity going to lung. 
A microbiologic assay with E. coli inocula- 
tion of BBL seed agar incubated at 30° for 16 to 
18 hr was performed at Bristol Laboratories. 
This assay was used to measure plasma mito 
levels in the first 10 subjects treated with 15 ml 
DSM. The lower limit of the assay is 0.01 
An HPLC assay has been developed for the 
determination of mito in human plasma. The 
method involves extraction of mito into an or- 
ganic solvent, injection of 2 to 20 p.l for HPLC 
analysis on a p.-Bondapak C18 reverse-phase 
column (Waters), and detection on a UV detec- 
tor at 365 nm wavelength. Quantitation was 
with an internal standard (porfiromycin) by the 
peak/height ratio method. This assay was used 
to measure plasma mito levels in the group of 
six subjects treated with 6 ml DSM. The lower 
limit of the assay is 25 ng/ml. 
Results 
Fig. 2 shows the systemic mito concentra- 
tion-time profile in one representative subject 
(Table III, subject 8) after hepatic artery injec- 
tion of mito alone and after mito with 15 ml 
microspheres. AUCs were calculated as repre- 
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sentative of relative systemic drug exposure. 
The ratio of AUC with mito plus microspheres 
and mito alone over 1 hr was 0.83, in this case 
indicating approximately 20% reduction in 
systemic exposure when mito was injected 
with DSM. 
Table II shows the effects of concurrent DSM 
on systemic mito exposure compared with he- 
patic arterial mito alone in 10 subjects. Two 
subjects were treated on two separate occasions. 
At each of the time intervals indicated, there 
was a reduction in the mean AUC when mito 
was injected with DSM. The effect was signifi- 
cant (paired t test, P <0.01).6 Table III shows 
the ratio of systemic exposure (AUCs) when 
mito is injected with DSM and when mito alone 
is given to each of these patients. In this group 
of patients there was some variability in the 
ratio of the AUCs, but in all cases there was a 
reduction in systemic exposure (17% to 70%) 
when mito was injected with DSM. There was a 
mean reduction in systemic exposure of 40% to 
45% over 1 hr. 
All subjects in this study received treatment 
with mito alone, followed by treatment with 
mito and DSM on a separate day. In order to 
exclude the possibility that the first dose of mito 
alone might influence the elimination of a sub- 
sequent dose, we measured plasma drug levels 
in four other subjects receiving mito (10 
mg/m2) alone on two consecutive days. In these 
cases there was an average 6% change in the 
systemic exposure (median 5.9%, range 0.7% 
to 10.4%) by prior treatment. In addition, in a 
second treatment course one of the 16 subjects 
subsequently received mito with DSM, fol- 
lowed by mito alone on a second day. The re- 
sults confirmed the lack of a sequential dose 
effect (data not shown). 
During the course of this investigation, all 
subjects underwent baseline nuclear angiogra- 
phy with TcMAA microspheres alone. In sub- 
sequent studies we observed significant inter- 
subject variability in shunting through the liver 
to the lungs when TcMAA microspheres were 
subsequently injected with 15 ml DSM. Based 
on this observation and the variability in reduc- 
tion of systemic exposure noted in the first 10 
subjects, we subsequently treated an additional 
six subjects with mito (10 mg/m2) alone and 
with DSM on separate days. Before treatment, 
Subject 
No. 0-15 min 0-30 min 0-60 min 
1 0.66 0.66 0.69 
0.70 0.71 0.75 
2 0.67 0.68 0.70 
0.52 0.58 0.62 
3 0.54 0.58 0.64 
4 0.46 0.49 0.54 
5 0.53 0.61 0.64 
6 0.59 0.58 0.54 
7 0.50 0.58 0.65 
8 0.88 0.85 0.83 
9 0.30 0.36 0.36 
10 0.41 0.36 0.28 
Mean 0.56 0.59 0.60 
Volume 34 
Number 2 
however, these subjects were scanned after 
the incremental doses of DSM spiked with 
TcMAA. This allowed us to determine the 
shunting (PSI) that occurred with increasing 
DSM doses (0 to 90 x 106 microspheres) in the 
individual subjects. These six subjects (Table 
IV) then received mito alone and mito with 6 ml 
(36 X 106 microspheres) DSM. Based on the 
incremental study, in all cases the magnitude of 
the shunt at this dose of DSM was known. The 
PSI ranged from 8% to 29% (mean 17.2%). 
Systemic exposure to mito (AUC) on both days 
was measured. Under these circumstances, the 
variability in reduction of systemic exposure 
(ratio of AUCs) seen in the first group of sub- 
jects was observed again. The reduction in ex- 
posure averaged about 35% (range 15% to 60%) 
in these subjects. There was some tendency for 
the reduction in systemic exposure to corre- 
spond to the magnitude of the shunt, although a 
larger number of subjects will be needed to 
confirm this. 
In all subjects the toxicity was limited to 
nonlife-threatening myelosuppression (three 
cases), transient rise in liver chemistries (eight 
cases), nausea (six cases), and pain in the right 
upper quadrant (three cases). Based on liver 
chemistry determinations there was subsequent 
improvement in liver function in all subjects. 
No objective response was seen in these heavily 
pretreated subjects. 
Discussion 
Liver involvement by cancer occurs fre- 
quently and is a major cause of death. Although 
most patients with primary hepatobiliary and 
metastatic tumors in the liver cannot be cured 
with surgical resection, some are, indicating 
regional confinement in such cases.17 27 In 
other cases, the cancer may be confined to the 
liver and yet may be surgically unresectable be- 
cause of anatomic location.'7' 19' 27' 28 Thus 
other effective methods for eradicating tumor 
liver may cure some patients and palliate the 
effects of the tumor in many more. 
The liver has a dual blood supply, and under 
normal circumstances, approximately one third 
of blood entering the liver comes from the he- 
patic artery and two thirds from the portal 
vein."' 31 A number of investigations have 
shown that hepatic tumors derive most of their 
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Table IV. Ratio of systemic mitomycin 
exposure (AUC) with (6 ml) microspheres and 
without microspheres (six subjects) 
blood from the hepatic artery .2' 4. 5' 2" On the 
other hand, the liver parenchyma is able to sur- 
vive and function on the portal blood supply 
alone. Thus the liver has served as a useful 
model for the development of new techniques 
and approaches to regional therapy. Recent de- 
velopments in drug delivery techniques make 
possible a variety of clinical pharmacologic 
studies based on selective manipulation of the 
tumor microvasculature.12' 14 TcMAA has been 
given by hepatic arterial injection to patients 
with liver tumors to determine drug flow distri- 
bution."' 25 These albumin particles (30 to 40 
Amin diameter) are held in the first precapillary 
arteriole they encounter. Thus the relative den- 
sity of TcMAA should relate directly to the rel- 
ative density of the microcirculation patent at 
the time of injection. Angiographically hyper- 
vascular and hypovascular tumors both ap- 
pear to trap more TcMAA than the surrounding 
normal liver (as defined by technetium-99m 
sulfer colloid (TcSC) liver scans). Many small 
tumor nodules appear to be uniformly hy- 
pervascular, whereas larger nodules appear to 
have a rim of increased activity surrounding 
a relatively hypovascular core.2' This obser- 
vation corresponds to the findings of others 
that suggest that the areas of active tumor pro- 
liferation at the periphery of tumor nodules are 
vascular." 5 
Biodegradable starch microspheres, 40 ,um in 
diameter, have been introduced into cancer 
therapy .3' 8' 29 When injected into the hepatic 
artery, they lodge in the microvasculature and 
can block flow for 15 to 30 min. Coincident 
with this obstruction, intrahepatic shunting may 
Subject 
No. PSI 0-15 min 0-30 min 0-60 min 
1 8 0.42 0.42 0.48 
2 10 0.56 0.64 0.67 
3 10 0.58 0.60 0.66 
4 21 0.52 0.65 0.73 
5 25 0.76 0.72 0.68 
6 29 0.85 0.82 0.82 
Mean 17.2 0.62 0.64 0.67 
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occur. The magnitude of the shunting appears to 
be related to the dose of DSM, although a sig- 
nificant baseline shunt may also be present." 
As expected, the shunt may adversely affect the 
reduction in systemic exposure and ultimately 
will determine the optimal dose of DSM se- 
lected for therapy. This finding may have impli- 
cations for the design of other studies involving 
hepatic arterial drug injection. Administration 
of an optimal quantity of starch microspheres in 
an appropriate drug solution should lead to a 
holdup of the drug solution in the microcircula- 
tion. Because this obstruction is temporary, re- 
peated treatment is possible. Delivery of the 
drug solution within the tissue should be pro- 
portional to the microcirculation volume, which 
is proportional, in turn, to the number of micro- 
spheres entrapped in a given region of the tissue 
analogous to the TcMAA studies. 
Finally, in previous studies hepatic extraction 
of mito was found to be 5% to 10% by direct 
arteriovenous sampling and by a comparison of 
systemic exposure with intravenous and hepatic 
arterial administration." From our report it can 
be seen that microspheres induce a fourfold to 
ninefold increase in hepatic mito deposition and 
extraction (from 5% to 10% to 40% to 45%). 
Unlike mito, BCNU is known to break down 
spontaneously in plasma. This may explain 
the difference in enhanced regional selectivity 
when each of these drugs is given with DSM. 
The absence of significant hepatotoxicity or 
myelosuppression is encouraging. An attempt 
to exploit this improved regional selectivity 
with repeated doses of hepatic arterial mito with 
microspheres is under way. 
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